Neuroendocrine tumors are the maliganancies that starts in specialized cells called neuroendocrine cells. Neuroendocrine cells have traits and characteristics similar to those of hormone-producing cells and nerve cells. Neuroendocrine tumours are rare and can develop in any part of the body. The lungs, appendix, small intestine, rectum, and pancreas are the most major areas for neuroendocrine tumours. The treatment options for neuroendocrine tumors are, chemotherapy, surgery and radiation therapy.
The "Global Neuroendocrine Tumor Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the neuroendocrine tumor treatment market with detailed market segmentation by drugs, indication and end-user. The report provides key statistics on the market status of the leading neuroendocrine tumor treatment market players and offers key trends and opportunities in the market.
- Based on drugs the market is segmented as, Everolimus, Suininib Malate, Lu-Dotate, Lanreotide and Octreotide.
- Based on indication the market is segmented as, Gastrointestinal NET, Lung NET, Pancreatic NET, and Others NET.
- Based on end user the market is segmented as, Hospitals, Oncology Centers and Others.
- Increasing prevalence of neuroendocrine cancers is the key driving factor for the market growth.
- Rising screening activities to detect cancers at early stage for better outlook of disease is also expected to spur the market growth.
- Presence of advanced diagnostic imaging tests, advancement in healthcare infrastructure are likely to boost market growth.
- Extensive R&D activities to develop novel and targeted therapies for management of NET.
- However, high cost of NET treatment and risk of side effects after treatment are expected to restrain market growth during the forecast period.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The neuroendocrine tumor treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the neuroendocrine tumor treatment market in these regions.
IMPACT OF COVID-19 ON NEUROENDOCRINE TUMOR TREATMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for neuroendocrine tumor treatment drugs and therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for neuroendocrine tumor treatment and drugs . According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
The report covers key developments in the neuroendocrine tumor treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from neuroendocrine tumor treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for neuroendocrine tumor treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the neuroendocrine tumor treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Pfizer Inc.
- Novartis AG
- Ipsen Pharma
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Lantheus Medical Imaging, Inc
- Dauntless Pharmaceuticals
- Exelixis, Inc
- AVEO Oncology
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.